Last updated: October 25, 2026
MAXZIDE-25 is the fixed-dose combination of triamterene 37.5 mg and hydrochlorothiazide 25 mg. Its commercial profile is mature and largely genericized. The product has limited standalone revenue visibility, no meaningful remaining exclusivity, low switching costs for prescribers, and little evidence of a durable brand premium. Financial performance is driven by prescription volume, contract pricing, manufacturing efficiency, and reimbursement rather than patent protection.
What is MAXZIDE-25 and how is it used?
MAXZIDE-25 combines a potassium-sparing diuretic, triamterene, with the thiazide diuretic hydrochlorothiazide. The product is used to treat hypertension and edema in patients for whom potassium depletion from hydrochlorothiazide is a concern.
| Attribute |
MAXZIDE-25 |
| Active ingredients |
Triamterene 37.5 mg and hydrochlorothiazide 25 mg |
| Dosage form |
Oral tablet |
| Therapeutic category |
Diuretic; antihypertensive |
| FDA pathway |
Abbreviated New Drug Application equivalents and legacy NDA product |
| Biosimilar exposure |
None |
| Main substitutes |
Generic triamterene/hydrochlorothiazide, hydrochlorothiazide, chlorthalidone, indapamide, spironolactone, amiloride |
| Primary commercial channel |
Retail and mail-order pharmacy |
| Current market position |
Mature, low-growth generic combination product |
The combination is pharmacologically differentiated from hydrochlorothiazide alone because triamterene reduces potassium loss. That benefit is clinically relevant but does not create substantial commercial differentiation because physicians can prescribe the individual components separately.
When did MAXZIDE-25 lose exclusivity?
MAXZIDE-25 lost practical exclusivity decades ago. The product’s commercial market is now populated by generic manufacturers, and the active ingredients are long-established small molecules.
The product does not have the characteristics of a protected specialty pharmaceutical:
- No biologic exclusivity period applies.
- No meaningful new chemical entity exclusivity remains.
- No current market exclusivity appears to restrict generic substitution.
- The active ingredients have extensive prior clinical and manufacturing history.
- Generic manufacturers can compete through ANDA approvals and therapeutically equivalent products.
The FDA Orange Book remains the controlling reference for listed patents, regulatory exclusivity, and therapeutic-equivalence information. Available FDA records do not indicate a commercially meaningful, active patent barrier protecting the core MAXZIDE-25 combination.[1]
What patents protect MAXZIDE-25?
No current patent estate appears to provide material protection for MAXZIDE-25’s active ingredients, dosage strengths, or basic combination concept.
Core composition patents
The composition of matter for hydrochlorothiazide and triamterene is long expired. Any historical patents covering the compounds themselves cannot prevent current generic manufacture.
The fixed-dose combination also has an old commercial history. Combination-product protection, to the extent it existed, would have expired before the current generic market developed. The principal commercial risk is therefore price erosion, not patent litigation.
Formulation patents
The standard MAXZIDE-25 tablet does not appear to depend on a modern extended-release, abuse-deterrent, transdermal, injectable, or device-linked formulation. That limits the opportunity for follow-on formulation patents.
A manufacturer could pursue patents covering:
- Excipients
- Tablet hardness or dissolution characteristics
- Manufacturing processes
- Packaging or stability systems
- Alternative dosage strengths
- Fixed-dose combination ratios
Those claims would face substantial validity and infringement challenges because the product is technically simple and the active ingredients are well established. Process or formulation claims would not necessarily prevent generic products with different manufacturing methods.
Method-of-use patents
MAXZIDE-25 is used for hypertension and edema, which are established indications. Method-of-use patents for these uses would face significant prior-art and obviousness risks. Any historical use patents would not create a meaningful current barrier to generic substitution.
What is the FDA regulatory status of MAXZIDE-25?
MAXZIDE-25 is an FDA-approved oral diuretic combination. The regulatory framework is mature, and generic manufacturers can rely on the established safety and efficacy record through ANDA pathways, subject to bioequivalence and product-quality requirements.[2]
Key regulatory characteristics include:
| Regulatory issue |
Assessment |
| New drug approval risk |
Low for generic entrants using established active ingredients |
| Bioequivalence |
Required for ANDA approval |
| Clinical-trial burden |
Lower than for a new chemical entity |
| Manufacturing burden |
Standard solid-dose pharmaceutical controls |
| REMS requirement |
No major product-specific REMS barrier is associated with the combination |
| Substitution |
Generally supported where an approved therapeutically equivalent generic is available |
| Regulatory differentiation |
Limited |
The main regulatory risks relate to manufacturing quality, dissolution, content uniformity, stability, and supply continuity. Those risks can affect individual suppliers but do not protect the brand franchise.
How many patents cover MAXZIDE-25?
No material active patent estate appears to cover the core product. The relevant protection can be summarized as follows:
| Patent category |
Current commercial significance |
| Triamterene composition patent |
Expired |
| Hydrochlorothiazide composition patent |
Expired |
| Fixed-dose combination patent |
Historical or expired |
| Tablet formulation patent |
No material barrier identified |
| Method-of-use patent |
No material barrier identified |
| Manufacturing-process patent |
Potentially narrow and supplier-specific |
| Device or delivery-system patent |
Not applicable |
The absence of an enforceable patent estate does not eliminate all litigation risk. A manufacturer could still challenge a patent covering a particular process, formulation, or supplier-specific product. That risk is unlikely to support premium pricing for the overall MAXZIDE-25 market.
Are there Paragraph IV challenges involving MAXZIDE-25?
Paragraph IV litigation is not a central market event for MAXZIDE-25 because the product is already genericized and does not depend on an active branded patent barrier.
A generic applicant would use a Paragraph IV certification only if the reference product’s Orange Book listing included an unexpired patent relevant to the proposed ANDA. The absence of a meaningful current patent estate reduces the probability of a strategically important Paragraph IV campaign.
The competitive process is more likely to involve:
- ANDA approval.
- Product launch after regulatory clearance.
- Wholesale and pharmacy contracting.
- Price competition.
- Periodic supply disruptions or manufacturer exits.
This differs from products such as protected cardiovascular combinations, long-acting injectables, or complex drug-device products, where Paragraph IV litigation can determine market entry timing.
What is the Orange Book status of MAXZIDE-25?
The Orange Book is relevant for determining whether the reference product has listed patents, regulatory exclusivity, and therapeutically equivalent generic versions.[1] MAXZIDE-25 should be evaluated as a legacy small-molecule combination rather than as a protected branded product.
The commercial implications are:
- Orange Book patent listings do not appear to provide an effective barrier to generic competition.
- Therapeutic-equivalence listings support substitution when the generic product has the applicable FDA rating.
- Product-level sales are not separately disclosed by FDA.
- The existence of an NDA or legacy brand approval does not imply continuing exclusivity.
FDA listing status and marketing status can change as sponsors discontinue products, transfer applications, or update labeling. For commercial diligence, the key issue is the availability of approved generic equivalents, not the survival of the historical brand name.
How strong is the MAXZIDE-25 patent estate?
The patent estate is weak from a commercial-defense perspective.
| Patent-strength factor |
Assessment |
| Composition-of-matter protection |
None remaining |
| Remaining patent term |
No material term identified |
| Formulation complexity |
Low |
| Manufacturing complexity |
Low to moderate |
| Design-around difficulty |
Low |
| Generic substitution risk |
High |
| Litigation leverage |
Low |
| Brand-price protection |
Low |
The strongest potential barrier is not intellectual property. It is operational execution. A supplier with reliable API sourcing, validated manufacturing, FDA-compliant facilities, and stable pharmacy contracts can compete without needing a differentiated patent position.
What is the competitive landscape for MAXZIDE-25?
Competition comes from both direct generic equivalents and therapeutic substitutes.
Direct competitors
Direct competitors include generic triamterene/hydrochlorothiazide tablets in the same or similar strengths. These products compete primarily on:
- Wholesale acquisition cost
- Pharmacy reimbursement
- Medicaid and commercial formulary status
- Supply reliability
- Wholesaler service levels
- Contract terms
- FDA manufacturing history
Therapeutic competitors
Physicians may use separate hydrochlorothiazide and triamterene prescriptions, although the fixed-dose product offers simpler dosing. Other alternatives include:
- Hydrochlorothiazide monotherapy
- Chlorthalidone
- Indapamide
- Spironolactone
- Amiloride
- Loop diuretics for selected edema indications
Chlorthalidone and indapamide can compete in hypertension because of their longer duration of action. Spironolactone competes where aldosterone antagonism is clinically preferred. Separate-component prescribing can reduce the addressable market for the fixed-dose tablet.
What are the market dynamics for MAXZIDE-25?
MAXZIDE-25 is a mature generic-market product with limited volume growth. Demand is influenced by the broader hypertension and edema populations, but the product itself has low strategic visibility.
Demand drivers
Demand is supported by:
- Persistent hypertension prevalence
- Continued use of diuretics in primary care
- Preference for fixed-dose combinations in some patients
- Use in patients who develop hypokalemia on thiazide therapy
- Low acquisition cost relative to newer branded therapies
Demand constraints
Demand is limited by:
- Availability of separate-component prescriptions
- Use of newer guideline-preferred antihypertensives
- Physician preference for chlorthalidone or other thiazide-like agents
- Hyperkalemia risk from triamterene
- Renal-function restrictions
- Generic substitution and low brand loyalty
The labeling warns against use in patients with significant renal impairment or pre-existing hyperkalemia. Concomitant potassium supplementation and certain renin-angiotensin system drugs can increase safety concerns.[3]
What is the financial trajectory of MAXZIDE-25?
There is no reliable public product-level revenue series for MAXZIDE-25. Generic manufacturers generally report cardiovascular and oral-solid-dose revenue in aggregated portfolios rather than by individual low-priced product.
The likely financial trajectory is:
| Period |
Financial profile |
| Original branded period |
Higher price and stronger product-level economics |
| Early generic entry |
Rapid price compression and share fragmentation |
| Mature generic period |
Stable or declining nominal revenue |
| Current market |
Low-margin, volume-dependent product with limited standalone disclosure |
Revenue exposure is likely concentrated in manufacturing and distribution economics rather than brand royalties. A supplier may generate positive contribution margin if it has efficient production and stable volume, but the product is unlikely to be a major earnings driver for a diversified pharmaceutical company.
Margin characteristics
Expected margin pressure comes from:
- Multiple approved suppliers
- Pharmacy benefit manager contracting
- Wholesaler discounts
- Reimbursement compression
- Low switching costs
- Periodic tender competition
- API and packaging costs
- FDA compliance and remediation expenses
Margins can temporarily improve when competitors experience shortages or manufacturing disruptions. Those gains are usually unstable because additional suppliers can re-enter or increase production.
Revenue exposure
For a generic manufacturer, MAXZIDE-25 is more likely to be:
- A portfolio-completion product
- A low-cost oral-solid-dose SKU
- A pharmacy-account retention product
- A source of incremental manufacturing utilization
It is unlikely to be a material standalone revenue asset unless a company has unusually concentrated share or temporary supply scarcity.
What generic launch scenarios exist for MAXZIDE-25?
The main launch scenarios are operational rather than patent-driven.
Base case: fragmented generic supply
Multiple suppliers remain active, pricing stays compressed, and unit demand is broadly stable. Revenue declines gradually as reimbursement falls and prescribing shifts toward alternative diuretics.
Upside case: supplier consolidation
If manufacturers exit because of low margins, remaining suppliers may gain volume and improve pricing. This scenario can increase short-term revenue and gross margin but may attract new entrants.
Disruption case: manufacturing shortage
A facility warning letter, API shortage, recall, or capacity reduction could create temporary product scarcity. The impact would depend on inventory, alternative suppliers, and the availability of separate triamterene and hydrochlorothiazide products.
Downside case: substitution and formulary erosion
Increased use of chlorthalidone, indapamide, spironolactone, or separate-component therapy could reduce demand. The effect would be gradual because MAXZIDE-25 remains an inexpensive established option.
What patent litigation and settlement agreements affect MAXZIDE-25?
No major current patent litigation or settlement structure appears to determine market access for MAXZIDE-25. The product’s market is not organized around an at-risk generic launch against an active branded patent.
Any historical settlement agreements would have limited current commercial relevance unless they contain continuing supply, licensing, or authorized-generic provisions. Those terms are unlikely to shape the overall market in the same way as settlements involving blockbuster products.
How does MAXZIDE-25 compare with competing drug products?
| Product |
Main advantage |
Main commercial limitation |
| MAXZIDE-25 |
Fixed-dose potassium-sparing and thiazide combination |
Mature generic pricing and hyperkalemia risk |
| Generic hydrochlorothiazide |
Low cost and familiarity |
Potassium depletion |
| Chlorthalidone |
Long duration and guideline use |
Electrolyte abnormalities and tolerability |
| Indapamide |
Thiazide-like efficacy |
Smaller commercial footprint |
| Spironolactone |
Useful in resistant hypertension and heart failure |
Endocrine effects and hyperkalemia |
| Amiloride combinations |
Potassium-sparing effect |
Smaller market and limited differentiation |
MAXZIDE-25 competes effectively on convenience and price. It does not compete through novel pharmacology, delivery technology, or proprietary clinical evidence.
What geographic coverage and manufacturing barriers apply?
MAXZIDE-25 and equivalent products can be manufactured under standard oral-solid-dose controls in multiple jurisdictions. The main geographic issues are regulatory approval, local substitution rules, reimbursement, and supply-chain economics.
Manufacturing barriers include:
- Qualified triamterene and hydrochlorothiazide API suppliers
- Content uniformity for low-dose triamterene
- Dissolution and stability performance
- FDA inspection compliance
- Packaging and labeling controls
- Reliable distribution to wholesalers and pharmacies
These barriers can cause temporary supply advantages but are not equivalent to patent protection. A manufacturer with a compliant facility and established distribution network can generally replicate the commercial product.
Key Takeaways
- MAXZIDE-25 is a mature fixed-dose combination of triamterene 37.5 mg and hydrochlorothiazide 25 mg.
- Practical exclusivity ended decades ago, and the market is genericized.
- No material active patent estate appears to protect the core product.
- Paragraph IV litigation is not a central determinant of current market access.
- Product-level revenue is not publicly disclosed in a reliable, standalone series.
- Financial performance depends on volume, contracting, manufacturing efficiency, and supply continuity.
- Generic competition and therapeutic substitution limit pricing power.
- The principal commercial upside comes from supplier exits or temporary shortages, not patent enforcement.
- Biosimilar risk is irrelevant because MAXZIDE-25 is a small-molecule tablet.
- The product has limited strategic value unless bundled into a broader generic portfolio.
FAQs
Is MAXZIDE-25 still commercially available?
MAXZIDE-25 has a long-established regulatory and commercial history, but availability can vary by manufacturer, strength, pharmacy, and market. Generic triamterene/hydrochlorothiazide products are the main source of supply.
Is MAXZIDE-25 protected by a patent?
No material current patent protection appears to cover the basic triamterene/hydrochlorothiazide combination, its standard tablet dosage form, or its established indications.
Can a generic manufacturer launch MAXZIDE-25 without clinical trials?
A generic manufacturer generally uses the ANDA pathway, which requires pharmaceutical equivalence and bioequivalence rather than a full new clinical efficacy program. FDA approval remains subject to product-quality and manufacturing requirements.[2]
Does MAXZIDE-25 have biosimilar competition?
No. Biosimilars apply to biologic products. MAXZIDE-25 is a conventional small-molecule oral tablet and competes with generic equivalents.
What is the main investment risk for a MAXZIDE-25 manufacturer?
The main risks are price erosion, low reimbursement, manufacturing compliance costs, supplier concentration, and declining demand from therapeutic substitution. Patent expiry is not the principal current risk because exclusivity has already ended.
References
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA). https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
-
U.S. Food and Drug Administration. (n.d.). MAXZIDE-25 prescribing information: Triamterene and hydrochlorothiazide tablets. DailyMed. https://dailymed.nlm.nih.gov/dailymed/
